The proper storage of research documents remains an essential aspect of the clinical trials process.
Improvements in image acquisition and read quality: A look at the value of standardization in oncology trials.
Industry Standard Research has recently released its 3rd annual "CRO Quality Benchmarking Report." The report not only profiles the delivery quality of leading CROs, but also provides a wealth of information that relates to larger industry trends, including the value of recruitment speed.
With significant technology advances in ECG recording through the years, the need to expand on traditional monitoring baselines-and include new variables such as time when designing clinical trial protocols-is important.
Transfer of material between the supply cahins can be time consuming and complicated
While order might be useful for smaller firms to do business, it is not useful in helping them to innovate.
Timely completion of clinical trials is the weak link in the drug development process, and there is no shortage of suggestions for how to improve it.
The new Clinical Trials Regulation introduces an overhaul of the existing regulation of clinical trials for medicinal products in the EU.
The country’s introduction of a new legal framework has it in sync with European law on clinical research.
Longer-term strategic issues are making already high-investment, high-risk decisions to place studies overseas even more complex.
How modeling and simulation clarified complex exposure levels and an orphan drug got approved.
How modeling and simulation clarified complex exposure levels and an orphan drug got approved.
Longer-term strategic issues are making already high-investment, high-risk decisions to place studies overseas even more complex.
The World Health Report 2013 argues that universal health coverage cannot be achieved without the evidence from scientific research, and in order to better manage healthcare, clinical research needs to keep up-to-date and advance in line with society in general.
A new solution will seamlessly and electronically exchange data from the RBM system to the EDC platform, and vice versa.
Bio-pharmaceutical companies are continually tasked with gathering more safety information and responding to requirements more quickly. Recent examples of significant changes in reporting requirements include 2010/84/EU and Regulation Number 1235/2010 on pharmacovigilance, and the 2012 European Medicines Agency (EMA) new guidelines on good pharmacovigilance practices.
Method designed to reduce the time gap between protocol approval and recruitment is examined.
Inevitably, the conversation consistently comes back to a simple philosophical debate?should software solutions be configurable or customizable?
Why do we audit our suppliers and what do we hope to achieve when we do?
Pilot study seeks to validate new and more granular outsourcing model classifications in differentiating performance across custom contract-service approaches.
Pediatric trials now feature increased modeling and analytics for safer drug dosing and response.
This article will focus on a case study example of a collaborative effort to share investigator, site, and study information across companies, and on the single data model that underpins it.
In the healthcare arena, the concept of patient-centeredness has expanded over the last 50 years, beginning as a term to describe patient engagement in self-health management and evolving to include various aspects of patient engagement in healthcare research.1
Cancer Research UK (CRUK) followed such advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials.
The implications and challenges of the placebo effect on regulatory agency product approval.
Automated eTMF solutions reduce costs, improve productivity, and enhance data management.
Conducting clinical research in the East brings a new group of challenges to sponsors